Takotsubo cardiomyopathy caused by infusion reaction to trastuzumab

Toshihiko Matsumoto; Takashi Oda; Yu Yoshida; Shogo Kimura; Hitomi Himei; Takao Tsuduki; Shinjiro Takagi; Masahiro Takatani; Hirofumi Morishita

doi:10.1007/s13691-019-00396-0

Takotsubo cardiomyopathy caused by infusion reaction to trastuzumab

Int Cancer Conf J. 2019 Dec 6;9(1):28-31. doi: 10.1007/s13691-019-00396-0. eCollection 2020 Jan.

Authors

Toshihiko Matsumoto¹, Takashi Oda¹, Yu Yoshida², Shogo Kimura¹, Hitomi Himei¹, Takao Tsuduki¹, Shinjiro Takagi¹, Masahiro Takatani¹, Hirofumi Morishita¹

Affiliations

¹ 1Department of Internal Medicine, Himeji Red Cross Hospital, 1-12-1, Shimoteno, Himeji, Hyogo 6708540 Japan.
² 2Department of Cardiology, Himeji Red Cross Hospital, 1-12-1, Shimoteno, Himeji, Hyogo 6708540 Japan.

Abstract

Takotsubo cardiomyopathy (TCM) is also known as stress-induced cardiomyopathy. The occurrence of TCM due to infusion reaction is extremely rare. A 65-year-old man began receiving trastuzumab monotherapy for gastric cancer. However, he developed an infusion reaction after administration. Electrocardiography revealed negative T waves, ST segment elevation, and apical akinesis and hypokinesis of the left ventricle with apical ballooning in the systole and diastole. Furthermore, troponin I and creatinine kinase (CK) levels and CK-myocardial band were elevated. Based on these findings, he was diagnosed with TCM. This is the first report of TCM due to an infusion reaction.

Keywords: Chemotherapy; Infusion reaction; Takotsubo cardiomyopathy.

Publication types

Case Reports